

**PCOL3022**

Neuropharmacology

S2 2020

## Table of Contents

<b>Lecture 1:</b> VGICs and Targets of Drug Action.....	3
<b>Lecture 2:</b> LGICs and Targets of Drug Action.....	6
<b>Lecture 3:</b> G-Protein Coupled Receptors Part 1.....	9
<b>Lecture 4:</b> G-Protein Coupled Receptors Part 2.....	12
<b>Lecture 5:</b> Transporters as Targets of Drug Action.....	15
<b>Lecture 6:</b> Cellular Techniques in Neuropharmacology.....	18
<b>Lecture 7:</b> Molecular Techniques in Neuropharmacology.....	21
<b>Lecture 8:</b> Monoamines.....	24
<b>Lecture 9:</b> Neuropeptides.....	27
<b>Lecture 10:</b> Genetic Techniques in Neuropharmacology.....	31
<b>Lecture 11:</b> Behavioural Neuropharmacology.....	34
<b>Lecture 12:</b> Opioids and Pain.....	38
<b>Lecture 13:</b> Chronic Pain Therapies.....	42
<b>Lecture 14:</b> Migraine and its Treatment.....	47
<b>Lecture 15:</b> Neuroadaptive Basis of Addiction.....	51
<b>Lecture 16:</b> Treatment of Addiction.....	55
<b>Lecture 17:</b> Cannabinoid Therapies for CNS Disorders.....	58
<b>Lecture 18:</b> Epilepsy (Anticonvulsants).....	61
<b>Lecture 19:</b> Mood Disorders (Antidepressants).....	64
<b>Lecture 20:</b> Anxiety (Sedatives, Hypnotics and Anxiolytics).....	68
<b>Lecture 21:</b> Schizophrenia (Antipsychotic).....	71
<b>Lecture 22:</b> Neuroimmune/Neuroinflammatory Diseases and Therapies.....	75
<b>Lecture 23:</b> Parkinson’s Disease and Movement Disorders.....	78
<b>Lecture 24:</b> Drugs to Treat Dementia and Improve Cognition.....	80

## Lecture 18 – Anticonvulsants

### *L01: Define epilepsy.*

- A disorder of the brain characterised by an enduring predisposition to generate epileptic seizures
- Only need the occurrence of one unprovoked seizure to be diagnosed (don't want to wait till you have a second one before they treat you!)
- Reasons for seizure: head trauma, high fever (especially in children), alcohol withdrawal, dehydration

### *L02: Describe the different types of seizures.*

- Focal (partial) seizure
  - Activation of neurons in a relatively small, discrete region
  - Clinical manifestation reflects region of brain where they occur (can be sensory or motor defects)
  - Complex partial seizures (temporal lobe epilepsy): impairment of consciousness (symptoms – familiarity, strangeness, automatisms (physical tics), hallucinations)
- Generalised seizure
  - Characterised by involvement of both hemispheres and widespread neuronal activation
  - Can have progression from focal to generalised seizures
  - Stages:
    1. Tonic: extension of the extremities (rigid stretching)
    2. Atonic: sudden loss of muscle tone (hence falling over)
    3. Clonic (myoclonic): repetitive muscle twitching
    4. Tonic-clonic (grand mal): distinct tonic phase followed by a clonic phase (full body spasms with intermittent relaxation)
    5. Generalised absence seizures (petit mal): brief lapse of consciousness (can look quite mild but can be a big problem, especially if driving)

### *L03: Describe the mechanism of action of antiepileptic drugs.*

- Need balance of excitation and inhibition
  - Too much excitation leads to convulsions, anxiety, high BP, insomnia → increased levels of glutamate and decreased levels of GABA
  - Too much inhibition leads to sleep, sedation, depression, coma, low BP → increased levels of GABA and decreased levels of glutamate
- Anticonvulsants
  - 25-40% of newly diagnosed epilepsy patients are drug resistant (to at least two anticonvulsant drugs)
  - Huge variability in disease management
    - Compliance: disease for life
    - Monitor plasma levels: use this to monitor patient's compliance to treatment
  - Toxicity issues long term

- Mechanisms of anticonvulsants (green is about ↓ excitation; red is about ↑ inhibition)

1. Enhance Na<sup>+</sup> channel inactivation – reduce firing frequency of neurons

**PHENYTOIN**

- Na<sup>+</sup> channel blockers
- Na<sup>+</sup> channels are critical for initiation and propagation of APs
- Enhance voltage gated Na<sup>+</sup> channel inactivation by reducing sustained high frequency firing of APs – therefore making it harder to open and thus reducing excitability
- Well tolerated (side effects: dizziness, nausea, headache)

2. Inhibit excitatory amino acid release – block Ca<sup>2+</sup> channels

**KEPPRA**

- Binds to neuronal synaptic vesicle glycoprotein 2A protein (typically used to release glutamate)
- Reduces neuronal excitability and glutamate release, thus reducing excitability

**ZARONTIN**

- Treats generalised absence seizures (lapse of consciousness)
- T-type Ca<sup>2+</sup> channel blocker
- Well tolerated (side effects: nausea, diarrhoea)

3. Block excitatory amino acid action

**FYCOMPA**

- Selective, non-competitive AMPA receptor antagonist
- Prevents ability of glutamate to bind to AMPA receptors on post-synaptic membrane
- Potent

4. Enhance GABA action

**BARBITURATES**

- Can act alone or enhance actions of GABA
- Acts on all GABA<sub>A</sub> receptors to prolong the 'open' time of the channel
- Not used as first-class drug anymore due to unwanted sedative effects
- Side effects: tiredness, anaemia, confusion

**BENZODIAZEPINES**

- Enhances the actions of GABA
- Increases the frequency of channel opening to increase inhibition
- Patients develop rapid tolerance
- Side effects: sleepiness, poor coordination

5. Inhibit GABA breakdown

**VIGABATRIN**

- Prevents breakdown of GABA
- Specific inhibitor of GABA transaminase (breaks down GABA)
- Side effects: fatigue, dizziness, loss of peripheral vision (need to monitor this constantly)

6. Inhibit GABA uptake

**TIAGABINE**

- GAT1 inhibitor
- Increases extracellular GABA levels
- Well tolerated (side effects: sleepiness, tremor, anxiety)

- Other commonly used drugs with unknown mechanisms
  - Epilum
    - May use mechanisms 1, 2 and 5?
    - A use-dependent Na<sup>+</sup> channel blocker and a Ca<sup>2+</sup> channel blocker (therefore decreases excitation)
    - Increases the levels of GABA (therefore increases inhibition)
    - Well tolerated (side effects: dizziness, weight gain, cannot OD as no nitrogen)
  - Topomax
    - May use mechanisms 1, 3 and 4?
    - Inhibits voltage-dependent Na<sup>+</sup> channels (therefore decreases excitation)
    - Antagonist at AMP receptors (therefore increases inhibition)
    - Moderately tolerated (side effects: dizziness, word retrieval problems, confusion)
  - Felbatol
    - May use mechanisms 1, 3 and 4?
    - Inhibits voltage-dependent Na<sup>+</sup> channels (therefore decreases excitation)
    - Antagonist at NMDA receptors
    - Positively modulates GABA<sub>A</sub> receptors (therefore increases inhibition)
    - Well tolerated (side effects: headache, weight loss, insomnia)
  - Gabapentin
    - Increases total GABA concentrations in CSF
    - Associated with decrease in NT release (mechanism 2)
    - Well tolerated (side effects: sleepiness, weight gain)

*L04: Describe the genetics of epilepsy and the functional effect of a mutation that causes epilepsy.*

- Brain is predisposed to seizure activity because neurons are so extensively interconnected – fine balance
- 25 genes have been found that are responsible for epilepsy
- All mutations known to cause epilepsy are found in ion channel subunits
- GABA<sub>A</sub> receptor mutation
  - Mutation in  $\gamma 2$  subunit GABA<sub>A</sub> receptor
  - Decrease in GABA<sub>A</sub> receptor amplitude
- Sodium channel mutation
  - Mutation in Na<sub>v</sub>1.1 channel which renders it non-functional (due to protein folding errors)
  - Why does Na<sup>+</sup> channel loss of function mutation cause epilepsy when most common drugs for epilepsy inhibit Na<sup>+</sup> channels?
    - Na<sup>+</sup> channels are found in GABAergic neurons so not the kind of Na<sup>+</sup> channels found in presynaptic excitatory system